BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, Friedman K, Ponzo F, Babb JS, Goldberg J. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16:795-803. [PMID: 26095785 DOI: 10.1016/s1470-2045(15)00054-6] [Cited by in Crossref: 417] [Cited by in F6Publishing: 382] [Article Influence: 52.1] [Reference Citation Analysis]
Number Citing Articles
1 Yang S, Pai J, Yao C, Huang C, Chen JL, Wang C, Chen K, Shieh M. SN38-loaded nanomedicine mediates chemo-radiotherapy against CD44-expressing cancer growth. Cancer Nano 2023;14:1. [DOI: 10.1186/s12645-022-00151-w] [Reference Citation Analysis]
2 Yang SJ, Pai JA, Shieh MJ, Chen JL, Chen KC. Cisplatin-loaded gold nanoshells mediate chemo-photothermal therapy against primary and distal lung cancers growth. Biomed Pharmacother 2023;158:114146. [PMID: 36584428 DOI: 10.1016/j.biopha.2022.114146] [Reference Citation Analysis]
3 Sasaki M, Tanaka M, Kojima Y, Nishie H, Shimura T, Kubota E, Kataoka H. Anti-tumor immunity enhancement by photodynamic therapy with talaporfin sodium and anti-programmed death 1 antibody. Mol Ther Oncolytics 2023;28:118-31. [PMID: 36726602 DOI: 10.1016/j.omto.2022.12.009] [Reference Citation Analysis]
4 Gaipl US, Grosu AL, Frey B, Rückert M, Schäfer H, Popp I. Strahlentherapie und Immuntherapie. Springer Reference Medizin 2023. [DOI: 10.1007/978-3-662-46764-0_177-1] [Reference Citation Analysis]
5 Takada M, Yoshimura M, Kotake T, Kawaguchi K, Uozumi R, Kataoka M, Kato H, Yoshibayashi H, Suwa H, Tsuji W, Yamashiro H, Suzuki E, Torii M, Yamada Y, Kataoka T, Ishiguro H, Morita S, Toi M. Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer. Sci Rep 2022;12:22397. [PMID: 36575361 DOI: 10.1038/s41598-022-27048-3] [Reference Citation Analysis]
6 Barsoumian HB, Sheth RA, Ramapriyan R, Hsu E, Gagea M, Crowley K, Sezen D, Williams M, Welsh JW. Radiation Therapy Modulates Tumor Physical Characteristics to Reduce Intratumoral Pressure and Enhance Intratumoral Drug Delivery and Retention. Adv Radiat Oncol 2023;8:101137. [PMID: 36632088 DOI: 10.1016/j.adro.2022.101137] [Reference Citation Analysis]
7 Nelson BE, Adashek JJ, Lin SH, Subbiah V. On target methods to induce abscopal phenomenon for Off‐Target effects: From happenstance to happenings. Cancer Medicine 2022. [DOI: 10.1002/cam4.5454] [Reference Citation Analysis]
8 Barker CA, Riaz N. A macrophage-activated abscopal effect. Nat Cancer 2022. [DOI: 10.1038/s43018-022-00464-0] [Reference Citation Analysis]
9 Dongye Z, Li J, Wu Y. Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity. Br J Cancer 2022;127:1584-94. [PMID: 35902641 DOI: 10.1038/s41416-022-01876-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
10 Barcellos-Hoff MH. The radiobiology of TGFβ. Semin Cancer Biol 2022;86:857-67. [PMID: 35122974 DOI: 10.1016/j.semcancer.2022.02.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Jungles KM, Holcomb EA, Pearson AN, Jungles KR, Bishop CR, Pierce LJ, Green MD, Speers CW. Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1022542] [Reference Citation Analysis]
12 Craig DJ, Ambrose S, Stanbery L, Walter A, Nemunaitis J. Systemic benefit of radiation therapy via abscopal effect. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.987142] [Reference Citation Analysis]
13 Nabrinsky E, Macklis J, Bitran J. A Review of the Abscopal Effect in the Era of Immunotherapy. Cureus 2022. [DOI: 10.7759/cureus.29620] [Reference Citation Analysis]
14 Ingrosso G, Bottero M, Becherini C, Caini S, Alì E, Lancia A, Ost P, Sanguineti G, Siva S, Zilli T, Francolini G, Bellavita R, Aristei C, Livi L, Detti B. A systematic review and meta-analysis on non-metastatic castration resistant prostate cancer: The radiation oncologist's perspective. Semin Oncol 2022:S0093-7754(22)00073-2. [PMID: 36192243 DOI: 10.1053/j.seminoncol.2022.09.005] [Reference Citation Analysis]
15 Wall I, Boulat V, Shah A, Blenman KRM, Wu Y, Alberts E, Calado DP, Salgado R, Grigoriadis A. Leveraging the Dynamic Immune Environment Triad in Patients with Breast Cancer: Tumour, Lymph Node, and Peripheral Blood. Cancers (Basel) 2022;14:4505. [PMID: 36139665 DOI: 10.3390/cancers14184505] [Reference Citation Analysis]
16 Pan P, Dong X, Chen Y, Ye JJ, Sun YX, Zhang XZ. A heterogenic membrane-based biomimetic hybrid nanoplatform for combining radiotherapy and immunotherapy against breast cancer. Biomaterials 2022;289:121810. [PMID: 36152517 DOI: 10.1016/j.biomaterials.2022.121810] [Reference Citation Analysis]
17 Karwacki J, Kiełbik A, Szlasa W, Sauer N, Kowalczyk K, Krajewski W, Saczko J, Kulbacka J, Szydełko T, Małkiewicz B. Boosting the Immune Response—Combining Local and Immune Therapy for Prostate Cancer Treatment. Cells 2022;11:2793. [DOI: 10.3390/cells11182793] [Reference Citation Analysis]
18 Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen D, Berglund A, Michael L, Aoki M, Wang M, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. The Lancet 2022;400:1008-19. [DOI: 10.1016/s0140-6736(22)01659-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Hartmann L, Osen W, Eichmüller OL, Kordaß T, Furkel J, Dickes E, Reid C, Debus J, Brons S, Abdollahi A, Moustafa M, Rieken S, Eichmüller SB. Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model. Cancer Letters 2022. [DOI: 10.1016/j.canlet.2022.215928] [Reference Citation Analysis]
20 Potiron V, Delpon G, Ollivier L, Vaugier L, Doré M, Guimas V, Rio E, Thillays F, Llagostera C, Moignier A, Josset S, Chiavassa S, Perennec T, Supiot S. [Clinical research in radiation oncology: how to move from the laboratory to the patient?]. Cancer Radiother 2022:S1278-3218(22)00161-5. [PMID: 35999162 DOI: 10.1016/j.canrad.2022.07.009] [Reference Citation Analysis]
21 Faroni L, Collie L, Gabrielli F, Baldotto C, Moraes F. Role of Stereotactic Radiation Therapy in Operable and Inoperable Early-Stage Non-small Cell Lung Cancer. Curr Treat Options Oncol 2022. [PMID: 35969313 DOI: 10.1007/s11864-022-01002-x] [Reference Citation Analysis]
22 Zhou K, Jiang Y, Feng S, Wang T, Wang L, Cao J, Jiao Y. Combining radiation with immune checkpoint inhibitors therapy for HCC: From the alteration of the immune microenvironment by radiotherapy. Radiation Medicine and Protection 2022. [DOI: 10.1016/j.radmp.2022.07.005] [Reference Citation Analysis]
23 Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther 2022;7:258. [PMID: 35906199 DOI: 10.1038/s41392-022-01102-y] [Reference Citation Analysis]
24 Baretti M, Zhu Q, Fu W, Meyer J, Wang H, Anders RA, Azad NS. Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer. Oncotarget 2022;13:907-17. [DOI: 10.18632/oncotarget.28255] [Reference Citation Analysis]
25 Hartmann L, Osen W, Eichmüller OL, Kordaß T, Furkel J, Dickes E, Reid C, Debus J, Brons S, Abdollahi A, Moustafa M, Rieken S, Eichmüller SB. Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model.. [DOI: 10.1101/2022.07.22.500608] [Reference Citation Analysis]
26 Sengedorj A, Hader M, Frey B, Fietkau R, Ott OJ, Gaipl US, Rückert M. Interaction of Radiotherapy and Hyperthermia with the Immune System: a Brief Current Overview. Curr Stem Cell Rep. [DOI: 10.1007/s40778-022-00215-y] [Reference Citation Analysis]
27 Kong Y, Zhao X, Xu M, Pan J, Ma Y, Zou L, Peng Q, Zhang J, Su C, Xu Z, Zhou W, Peng Y, Yang J, Zhou C, Li Y, Guo Q, Chen G, Wu H, Xing P, Zhang L. PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study. Front Immunol 2022;13:952066. [DOI: 10.3389/fimmu.2022.952066] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Xu H, Hong Z, Xu M, Kong Y, Ma Y, Shan C, Xing P, Zhang L. PRaG Therapy of Refractory Metastatic Gastric Cancer: A Case Report. Front Immunol 2022;13:926740. [DOI: 10.3389/fimmu.2022.926740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Sun R, Henry T, Laville A, Carré A, Hamaoui A, Bockel S, Chaffai I, Levy A, Chargari C, Robert C, Deutsch E. Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy? J Immunother Cancer 2022;10:e004848. [PMID: 35793875 DOI: 10.1136/jitc-2022-004848] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Balázs K, Kocsis ZS, Ágoston P, Jorgo K, Gesztesi L, Farkas G, Székely G, Takácsi-nagy Z, Polgár C, Sáfrány G, Jurányi Z, Lumniczky K. Prostate Cancer Survivors Present Long-Term, Residual Systemic Immune Alterations. Cancers 2022;14:3058. [DOI: 10.3390/cancers14133058] [Reference Citation Analysis]
31 Schlick B, Shields MD, Marin-Acevedo JA, Patel I, Pellini B. Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer. Curr Treat Options Oncol 2022. [PMID: 35716328 DOI: 10.1007/s11864-022-00989-7] [Reference Citation Analysis]
32 Hannan R, Dohopolski MJ, Pop LM, Mannala S, Watumull L, Mathews D, Gao A, Garant A, Arriaga YE, Bowman I, Chung J, Wang J, Ariizumi K, Ahn C, Timmerman R, Courtney K. Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer. Biomedicines 2022;10:1419. [DOI: 10.3390/biomedicines10061419] [Reference Citation Analysis]
33 Lucia F, Geier M, Schick U, Bourbonne V. Narrative Review of Synergistics Effects of Combining Immunotherapy and Stereotactic Radiation Therapy. Biomedicines 2022;10:1414. [PMID: 35740435 DOI: 10.3390/biomedicines10061414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Gill S, Nowak AK, Bowyer S, Endersby R, Ebert MA, Cook A. Clinical evidence for synergy between immunotherapy and radiotherapy (SITAR). J Med Imaging Radiat Oncol 2022. [PMID: 35699321 DOI: 10.1111/1754-9485.13441] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Sanborn RE, Schneiders FL, Senan S, Gadgeel SM. Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer. Am Soc Clin Oncol Educ Book 2022;42:1-14. [PMID: 35671433 DOI: 10.1200/EDBK_350967] [Reference Citation Analysis]
36 Li J, Wang M, Xu S, Li Y, Li J, Yu J, Zhu H. The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC. Front Pharmacol 2022;13:841623. [PMID: 35656295 DOI: 10.3389/fphar.2022.841623] [Reference Citation Analysis]
37 Bekker RA, Kim S, Pilon-thomas S, Enderling H. Mathematical modeling of radiotherapy and its impact on tumor interactions with the immune system. Neoplasia 2022;28:100796. [DOI: 10.1016/j.neo.2022.100796] [Reference Citation Analysis]
38 Woody S, Hegde A, Arastu H, Peach MS, Sharma N, Walker P, Ju AW. Survival Is Worse in Patients Completing Immunotherapy Prior to SBRT/SRS Compared to Those Receiving It Concurrently or After. Front Oncol 2022;12:785350. [DOI: 10.3389/fonc.2022.785350] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Buonanno M, Gonon G, Pandey BN, Azzam EI. The intercellular communications mediating radiation-induced bystander effects and their relevance to environmental, occupational, and therapeutic exposures. Int J Radiat Biol 2022;:1-19. [PMID: 35559659 DOI: 10.1080/09553002.2022.2078006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
40 Shaaban SG, Ebner D, Mohamad O. Particle Therapy and the Immune System. Principles and Practice of Particle Therapy 2022. [DOI: 10.1002/9781119707530.ch11] [Reference Citation Analysis]
41 Xu JY, Chen JN, Lei J, Hu M, Wu SG, Zhou J. Local treatment improves survival in patients with stage IVB cervical cancer. Gynecol Oncol 2022:S0090-8258(22)00254-2. [PMID: 35490033 DOI: 10.1016/j.ygyno.2022.04.013] [Reference Citation Analysis]
42 Liu Y, Beeraka NM, Liu J, Chen K, Song B, Song Z, Luo J, Liu Y, Zheng A, Cui Y, Wang Y, Jia Z, Song X, Wang X, Wang H, Qi X, Ren J, Wu L, Cai J, Fang X, Wang X, Sinelnikov MY, Nikolenko VN, Greeshma MV, Fan R. Comparative clinical studies of primary chemoradiotherapy versus S-1 and nedaplatin chemotherapy against stage IVb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial. BMJ Open 2022;12:e055273. [PMID: 35470188 DOI: 10.1136/bmjopen-2021-055273] [Reference Citation Analysis]
43 Ma L. From Photon Beam to Accelerated Particle Beam: Antimetastasis Effect of Combining Radiotherapy With Immunotherapy. Front Public Health 2022;10:847119. [PMID: 35425754 DOI: 10.3389/fpubh.2022.847119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Turchan WT, Pitroda SP, Weichselbaum RR. Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy. Neoplasia 2022;27:100782. [PMID: 35303578 DOI: 10.1016/j.neo.2022.100782] [Reference Citation Analysis]
45 Zhai D, An D, Wan C, Yang K. Radiotherapy: Brightness and darkness in the era of immunotherapy. Transl Oncol 2022;19:101366. [PMID: 35219093 DOI: 10.1016/j.tranon.2022.101366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
46 Cantini L, Laniado I, Murthy V, Sterman D, G.j.v. Aerts J. Immunotherapy for mesothelioma: moving beyond single immune check point inhibition. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.01.016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
47 Sato A, Bloy N, Galassi C, Jiménez-cortegana C, Klapp V, Aretz A, Guilbaud E, Yamazaki T, Petroni G, Galluzzi L, Buqué A. Quantification of cytosolic DNA species by immunofluorescence microscopy and automated image analysis. Radiation Oncology and Radiotherapy Part A 2022. [DOI: 10.1016/bs.mcb.2022.05.004] [Reference Citation Analysis]
48 Nishiga Y, Drainas AP, Baron M, Bhattacharya D, Barkal AA, Ahrari Y, Mancusi R, Ross JB, Takahashi N, Thomas A, Diehn M, Weissman IL, Graves EE, Sage J. Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect. Nat Cancer 2022;3:1351-66. [PMID: 36411318 DOI: 10.1038/s43018-022-00456-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Shaikh S. Molecular Imaging and Radiobiology. Advances in Imaging 2022. [DOI: 10.1007/978-981-16-9535-3_22] [Reference Citation Analysis]
50 Anderson R, Vallis K. Radionuclide Therapy and Immunomodulation. Nuclear Medicine and Immunology 2022. [DOI: 10.1007/978-3-030-81261-4_11] [Reference Citation Analysis]
51 Wen L, Tong F, Zhang R, Chen L, Huang Y, Dong X. The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy. Front Oncol 2021;11:799957. [PMID: 34956911 DOI: 10.3389/fonc.2021.799957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
52 Jing S, Jiang C, Ji X, Qiu X, Li J, Sun X, Zhu X. Study on Motion Management of Pancreatic Cancer Treated by CyberKnife. Front Oncol 2021;11:767832. [PMID: 34926273 DOI: 10.3389/fonc.2021.767832] [Reference Citation Analysis]
53 He H, Xu T, Li P, Jia G, Li X, Song Q. Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review. Front Oncol 2021;11:782646. [PMID: 34888252 DOI: 10.3389/fonc.2021.782646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Billing DL, Rimner A. Results of Radiation Therapy as Local Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. Cancers (Basel) 2021;13:5773. [PMID: 34830925 DOI: 10.3390/cancers13225773] [Reference Citation Analysis]
55 Yasmin-Karim S, Wood J, Wirtz J, Moreau M, Bih N, Swanson W, Muflam A, Ainsworth V, Ziberi B, Ngwa W. Optimizing In Situ Vaccination During Radiotherapy. Front Oncol 2021;11:711078. [PMID: 34765538 DOI: 10.3389/fonc.2021.711078] [Reference Citation Analysis]
56 Yang Y, Li X, Zhou P, Deng X, Wang Y, Dang Q, Zheng Y, Yang D. Survival Effects of Radiotherapy on Patients Newly Diagnosed with Distant Metastatic Nasopharyngeal Carcinoma in Non-High-Incidence Areas. Cancer Manag Res 2021;13:8169-78. [PMID: 34754237 DOI: 10.2147/CMAR.S334958] [Reference Citation Analysis]
57 Yokoi T, Oba T, Kajihara R, Abrams SI, Ito F. Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer. Sci Rep 2021;11:21992. [PMID: 34754037 DOI: 10.1038/s41598-021-01455-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 De Felice M, Tammaro M, Leopardo D, Ianniello GP, Turitto G. Moving towards the Future of Radio-Immunotherapy: Could We “Tailor” the Abscopal Effect on Head and Neck Cancer Patients? Immuno 2021;1:410-23. [DOI: 10.3390/immuno1040029] [Reference Citation Analysis]
59 Elbanna M, Chowdhury NN, Rhome R, Fishel ML. Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy. Front Oncol 2021;11:749496. [PMID: 34733787 DOI: 10.3389/fonc.2021.749496] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Wang C, Zainal NS, Chai SJ, Dickie J, Gan CP, Zulaziz N, Lye BKW, Sutavani RV, Ottensmeier CH, King EV, Abraham MT, Ismail SMB, Lau SH, Kallarakkal TG, Mun KS, Zain RB, Abdul Rahman ZA, Thomas GJ, Cheong SC, Savelyeva N, Lim KP. DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor. Front Immunol 2021;12:763086. [PMID: 34733290 DOI: 10.3389/fimmu.2021.763086] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
61 Link B, Torres Crigna A, Hölzel M, Giordano FA, Golubnitschaja O. Abscopal Effects in Metastatic Cancer: Is a Predictive Approach Possible to Improve Individual Outcomes? J Clin Med 2021;10:5124. [PMID: 34768644 DOI: 10.3390/jcm10215124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
62 Janopaul-Naylor JR, Shen Y, Qian DC, Buchwald ZS. The Abscopal Effect: A Review of Pre-Clinical and Clinical Advances. Int J Mol Sci 2021;22:11061. [PMID: 34681719 DOI: 10.3390/ijms222011061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
63 Meng L, Xu J, Ye Y, Wang Y, Luo S, Gong X. The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients. Front Immunol 2021;12:723609. [PMID: 34621270 DOI: 10.3389/fimmu.2021.723609] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
64 Ni J, Zhou Y, Wu L, Ai X, Dong X, Chu Q, Han C, Wang X, Zhu Z. Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial. Radiat Oncol 2021;16:177. [PMID: 34526044 DOI: 10.1186/s13014-021-01905-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
65 Lin YJ, Wei KC, Chen PY, Lim M, Hwang TL. Roles of Neutrophils in Glioma and Brain Metastases. Front Immunol 2021;12:701383. [PMID: 34484197 DOI: 10.3389/fimmu.2021.701383] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
66 Lazarus HM, Ragsdale CE, Gale RP, Lyman GH. Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time? Front Immunol 2021;12:706186. [PMID: 34484202 DOI: 10.3389/fimmu.2021.706186] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
67 Fleischmann M, Glatzer M, Rödel C, Tselis N. Radioimmunotherapy: future prospects from the perspective of brachytherapy. J Contemp Brachytherapy 2021;13:458-67. [PMID: 34484362 DOI: 10.5114/jcb.2021.108601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Turchan WT, Pitroda SP, Weichselbaum RR. Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold. Int J Mol Sci 2021;22:9573. [PMID: 34502479 DOI: 10.3390/ijms22179573] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
69 Alekseenko I, Kuzmich A, Kondratyeva L, Kondratieva S, Pleshkan V, Sverdlov E. Step-by-Step Immune Activation for Suicide Gene Therapy Reinforcement. Int J Mol Sci 2021;22:9376. [PMID: 34502287 DOI: 10.3390/ijms22179376] [Reference Citation Analysis]
70 Feller G, Khammissa RAG, Nemutandani MS, Feller L. Biological consequences of cancer radiotherapy in the context of oral squamous cell carcinoma. Head Face Med 2021;17:35. [PMID: 34446029 DOI: 10.1186/s13005-021-00286-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
71 Nesbit EG, Donnelly ED, Strauss JB. Treatment Strategies for Oligometastatic Breast Cancer. Curr Treat Options Oncol 2021;22:94. [PMID: 34426881 DOI: 10.1007/s11864-021-00889-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
72 Wang HY, Chang YC, Hu CW, Kao CY, Yu YA, Lim SK, Mou KY. Development of a Novel Cytokine Vehicle Using Filamentous Phage Display for Colorectal Cancer Treatment. ACS Synth Biol 2021;10:2087-95. [PMID: 34342970 DOI: 10.1021/acssynbio.1c00266] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
73 McGee HM, Marciscano AE, Campbell AM, Monjazeb AM, Kaech SM, Teijaro JR. Parallels Between the Antiviral State and the Irradiated State. J Natl Cancer Inst 2021;113:969-79. [PMID: 33252657 DOI: 10.1093/jnci/djaa190] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Trappetti V, Fazzari JM, Fernandez-Palomo C, Scheidegger M, Volarevic V, Martin OA, Djonov VG. Microbeam Radiotherapy-A Novel Therapeutic Approach to Overcome Radioresistance and Enhance Anti-Tumour Response in Melanoma. Int J Mol Sci 2021;22:7755. [PMID: 34299373 DOI: 10.3390/ijms22147755] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
75 Tranberg KG. Local Destruction of Tumors and Systemic Immune Effects. Front Oncol 2021;11:708810. [PMID: 34307177 DOI: 10.3389/fonc.2021.708810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
76 Chen L, Imamichi S, Tong Y, Sasaki Y, Onodera T, Nakamura S, Igaki H, Itami J, Masutani M. A Combination of GM-CSF and Released Factors from Gamma-Irradiated Tumor Cells Enhances the Differentiation of Macrophages from Bone Marrow Cells and Their Antigen-Presenting Function and Polarization to Type 1. Medicines (Basel) 2021;8:35. [PMID: 34357151 DOI: 10.3390/medicines8070035] [Reference Citation Analysis]
77 Qiu B, Kline C, Mueller S. Radiation in Combination With Targeted Agents and Immunotherapies for Pediatric Central Nervous System Tumors - Progress, Opportunities, and Challenges. Front Oncol 2021;11:674596. [PMID: 34277419 DOI: 10.3389/fonc.2021.674596] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
78 Smolenov EI, Afonin GV, Usachev VS, Kudryavtsev DD, Kolobaev IV, Ivanov SA. The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancer. Issled prakt med (Print) 2021;8:109-123. [DOI: 10.17709/2409-2231-2021-8-2-10] [Reference Citation Analysis]
79 Green M, Van Nest SJ, Soisson E, Huber K, Liao Y, McBride W, Dominello MM, Burmeister J, Joiner MC. Three discipline collaborative radiation therapy (3DCRT) special debate: We should treat all cancer patients with hypofractionation. J Appl Clin Med Phys 2020;21:7-14. [PMID: 32602186 DOI: 10.1002/acm2.12954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
80 Wu M, Liu J, Seery S, Meng X, Yue J. Cytoreductive Nephrectomy Promoted Abscopal Effect of Camrelizumab Combined With Radiotherapy for Metastatic Renal Cell Carcinoma: A Case Report and Review of the Literature. Front Immunol 2021;12:646085. [PMID: 34211459 DOI: 10.3389/fimmu.2021.646085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Knispel S, Stang A, Zimmer L, Lax H, Gutzmer R, Heinzerling L, Weishaupt C, Pföhler C, Gesierich A, Herbst R, Kaehler KC, Weide B, Berking C, Loquai C, Utikal J, Terheyden P, Kaatz M, Schlaak M, Kreuter A, Ulrich J, Mohr P, Dippel E, Livingstone E, Becker JC, Weichenthal M, Chorti E, Gronewold J, Schadendorf D, Ugurel S. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG. J Immunother Cancer 2020;8:e000395. [PMID: 32371460 DOI: 10.1136/jitc-2019-000395] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
82 Onn A, Gottfried T, Stemmer A, Appel S, Lawrence YR, Urban D, Beller T, Daher S, Bar J. Real-World Analysis of the Impact of Radiotherapy on Immunotherapy Efficacy in Non-Small Cell Lung Cancer. Cancers (Basel) 2021;13:2800. [PMID: 34199805 DOI: 10.3390/cancers13112800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
83 Shen J, Yan J, Zhu S, Kong W, Zou Z, Liu J, Li S, Liu B. The Efficacy and Safety of Hypofractionated Radiation Therapy With Tomotherapy for Advanced or Recurrent Hepatocellular Carcinoma. Front Oncol 2021;11:559112. [PMID: 34136374 DOI: 10.3389/fonc.2021.559112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
84 Fiorica F, Tebano U, Gabbani M, Perrone M, Missiroli S, Berretta M, Giuliani J, Bonetti A, Remo A, Pigozzi E, Tontini A, Napoli G, Luca N, Grigolato D, Pinton P, Giorgi C. Beyond Abscopal Effect: A Meta-Analysis of Immune Checkpoint Inhibitors and Radiotherapy in Advanced Non-Small Cell Lung Cancer. Cancers (Basel) 2021;13:2352. [PMID: 34068133 DOI: 10.3390/cancers13102352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
85 Tan Y, Chen Q, Li X, Zeng Z, Xiong W, Li G, Li X, Yang J, Xiang B, Yi M. Pyroptosis: a new paradigm of cell death for fighting against cancer. J Exp Clin Cancer Res 2021;40:153. [PMID: 33941231 DOI: 10.1186/s13046-021-01959-x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 85] [Article Influence: 36.5] [Reference Citation Analysis]
86 Lippert TP, Greenberg RA. The abscopal effect: a sense of DNA damage is in the air. J Clin Invest 2021;131:148274. [PMID: 33938453 DOI: 10.1172/JCI148274] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
87 Ye H, Pang H, Shi X, Ren P, Huang S, Yu H, Wu J, Lin S. Nivolumab and Hypofractionated Radiotherapy in Patients With Advanced Lung Cancer: ABSCOPAL-1 Clinical Trial. Front Oncol 2021;11:657024. [PMID: 33968760 DOI: 10.3389/fonc.2021.657024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
88 Nguyen AT, Shiao SL, McArthur HL. Advances in Combining Radiation and Immunotherapy in Breast Cancer. Clin Breast Cancer 2021;21:143-52. [PMID: 33810972 DOI: 10.1016/j.clbc.2021.03.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
89 Zhao Y, Zhang T, Wang Y, Lu D, Du J, Feng X, Zhou H, Liu N, Zhu H, Qin S, Liu C, Gao X, Yang Z, Liu Z. ICAM-1 orchestrates the abscopal effect of tumor radiotherapy. Proc Natl Acad Sci U S A 2021;118:e2010333118. [PMID: 33785590 DOI: 10.1073/pnas.2010333118] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
90 Kong Y, Ma Y, Zhao X, Pan J, Xu Z, Zhang L. Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers. Front Oncol 2021;11:638873. [PMID: 33859942 DOI: 10.3389/fonc.2021.638873] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
91 Olivo Pimentel V, Marcus D, van der Wiel AM, Lieuwes NG, Biemans R, Lieverse RI, Neri D, Theys J, Yaromina A, Dubois LJ, Lambin P. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy. J Immunother Cancer 2021;9:e001764. [PMID: 33688020 DOI: 10.1136/jitc-2020-001764] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
92 Lei H, Shi M, Xu H, Bai S, Xiong X, Wei Q, Yang L. Combined Treatment of Radiotherapy and Immunotherapy for Urological Malignancies: Current Evidence and Clinical Considerations. Cancer Manag Res 2021;13:1719-31. [PMID: 33658847 DOI: 10.2147/CMAR.S288337] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Tubin S, Khan MK, Gupta S, Jeremic B. Biology of NSCLC: Interplay between Cancer Cells, Radiation and Tumor Immune Microenvironment. Cancers (Basel) 2021;13:775. [PMID: 33673332 DOI: 10.3390/cancers13040775] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
94 Rückert M, Deloch L, Frey B, Schlücker E, Fietkau R, Gaipl US. Combinations of Radiotherapy with Vaccination and Immune Checkpoint Inhibition Differently Affect Primary and Abscopal Tumor Growth and the Tumor Microenvironment. Cancers (Basel) 2021;13:714. [PMID: 33572437 DOI: 10.3390/cancers13040714] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
95 Procureur A, Simonaggio A, Bibault JE, Oudard S, Vano YA. Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments. Cancers (Basel) 2021;13:678. [PMID: 33567530 DOI: 10.3390/cancers13040678] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
96 Hörner-Rieber J, Klüter S, Debus J, Adema G, Ansems M, Verheij M. MR-Guided Radiotherapy: The Perfect Partner for Immunotherapy? Front Oncol 2020;10:615697. [PMID: 33604296 DOI: 10.3389/fonc.2020.615697] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
97 Li L, Chen R, Lin YT, Humayun A, Fornace AJ Jr, Li HH. 3,3'-Diindolylmethane Enhances Tumor Regression After Radiation Through Protecting Normal Cells to Modulate Antitumor Immunity. Adv Radiat Oncol 2021;6:100601. [PMID: 33490731 DOI: 10.1016/j.adro.2020.10.014] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Arrieta O, Barrón F, Ramírez-Tirado LA, Zatarain-Barrón ZL, Cardona AF, Díaz-García D, Yamamoto Ramos M, Mota-Vega B, Carmona A, Peralta Álvarez MP, Bautista Y, Aldaco F, Gerson R, Rolfo C, Rosell R. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial. JAMA Oncol 2020;6:856-64. [PMID: 32271354 DOI: 10.1001/jamaoncol.2020.0409] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 26.0] [Reference Citation Analysis]
99 Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, Rowe SP, Ross AE, Gorin MA, Deville C, Greco SC, Wang H, Denmeade SR, Paller CJ, Dipasquale S, DeWeese TL, Song DY, Wang H, Carducci MA, Pienta KJ, Pomper MG, Dicker AP, Eisenberger MA, Alizadeh AA, Diehn M, Tran PT. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. JAMA Oncol 2020;6:650-9. [PMID: 32215577 DOI: 10.1001/jamaoncol.2020.0147] [Cited by in Crossref: 388] [Cited by in F6Publishing: 428] [Article Influence: 194.0] [Reference Citation Analysis]
100 Campbell AM, Decker RH. Immunotherapy and Radiotherapy: New Strategies. Lung Cancer 2021. [DOI: 10.1007/978-3-030-74028-3_10] [Reference Citation Analysis]
101 Zheng-lin B, Galsky MD. Immune Checkpoint Blockade for Genitourinary Malignancies and the Abscopal Response. Interventional Urology 2021. [DOI: 10.1007/978-3-030-73565-4_35] [Reference Citation Analysis]
102 Bao C, Sun Y, Dwarakanath B, Dong Y, Huang Y, Wu X, Guha C, Kong L, Lu JJ. Carbon ion triggered immunogenic necroptosis of nasopharyngeal carcinoma cells involving necroptotic inhibitor BCL-x. J Cancer 2021;12:1520-30. [PMID: 33531997 DOI: 10.7150/jca.46316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
103 Chodavadia PA, Jacobs CD, Wang F, Salama JK, Kelsey CR, Clarke JM, Ready NE, Torok JA. Synergy between early-incorporation immunotherapy and extracranial radiotherapy in metastatic non-small cell lung cancer. Transl Lung Cancer Res 2021;10:261-73. [PMID: 33569310 DOI: 10.21037/tlcr-20-537] [Reference Citation Analysis]
104 Romesser PB, Crane CH. Pursuit of the Abscopal Effect. Digestive Disease Interventions 2020;04:369-372. [DOI: 10.1055/s-0040-1718905] [Reference Citation Analysis]
105 Criel M, Vandermeulen A, Vanhove K, Van De Kerkhove C, Nackaerts K, Lambrecht M, Berkovic P. Robust disease control following sequential immunotherapy and radiotherapy in a malignant pleural mesothelioma patient. Current Problems in Cancer: Case Reports 2020;2:100035. [DOI: 10.1016/j.cpccr.2020.100035] [Reference Citation Analysis]
106 Qian L, Liu F, Chu Y, Zhai Q, Wei X, Shao J, Li R, Xu Q, Yu L, Liu B, Liu Q. MicroRNA-200c Nanoparticles Sensitized Gastric Cancer Cells to Radiotherapy by Regulating PD-L1 Expression and EMT. Cancer Manag Res 2020;12:12215-23. [PMID: 33273858 DOI: 10.2147/CMAR.S279978] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
107 Sun R, Sundahl N, Hecht M, Putz F, Lancia A, Rouyar A, Milic M, Carré A, Battistella E, Alvarez Andres E, Niyoteka S, Romano E, Louvel G, Durand-Labrunie J, Bockel S, Bahleda R, Robert C, Boutros C, Vakalopoulou M, Paragios N, Frey B, Soria JC, Massard C, Ferté C, Fietkau R, Ost P, Gaipl U, Deutsch E. Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells. J Immunother Cancer 2020;8:e001429. [PMID: 33188037 DOI: 10.1136/jitc-2020-001429] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
108 Breen WG, Leventakos K, Dong H, Merrell KW. Radiation and immunotherapy: emerging mechanisms of synergy. J Thorac Dis 2020;12:7011-23. [PMID: 33282406 DOI: 10.21037/jtd-2019-cptn-07] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
109 Kumari S, Mukherjee S, Sinha D, Abdisalaam S, Krishnan S, Asaithamby A. Immunomodulatory Effects of Radiotherapy. Int J Mol Sci 2020;21:E8151. [PMID: 33142765 DOI: 10.3390/ijms21218151] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
110 Ji D, Song C, Li Y, Xia J, Wu Y, Jia J, Cui X, Yu S, Gu J. Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer. J Immunother Cancer 2020;8:e000826. [PMID: 33106387 DOI: 10.1136/jitc-2020-000826] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 10.7] [Reference Citation Analysis]
111 Barsoumian HB, Ramapriyan R, Younes AI, Caetano MS, Menon H, Comeaux NI, Cushman TR, Schoenhals JE, Cadena AP, Reilly TP, Chen D, Masrorpour F, Li A, Hong DS, Diab A, Nguyen QN, Glitza I, Ferrarotto R, Chun SG, Cortez MA, Welsh J. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer 2020;8:e000537. [PMID: 33106386 DOI: 10.1136/jitc-2020-000537] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 13.0] [Reference Citation Analysis]
112 Tinganelli W, Durante M. Carbon Ion Radiobiology. Cancers (Basel) 2020;12:E3022. [PMID: 33080914 DOI: 10.3390/cancers12103022] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 20.3] [Reference Citation Analysis]
113 Zhao X, Kong Y, Zhang L. Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Negative Patient With Refractory Metastatic Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review. Front Oncol 2020;10:1625. [PMID: 33014817 DOI: 10.3389/fonc.2020.01625] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
114 Yang W, Xiu Z, He Y, Huang W, Li Y, Sun T. Bip inhibition in glioma stem cells promotes radiation-induced immunogenic cell death. Cell Death Dis 2020;11:786. [PMID: 32963254 DOI: 10.1038/s41419-020-03000-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
115 Candas-Green D, Xie B, Huang J, Fan M, Wang A, Menaa C, Zhang Y, Zhang L, Jing D, Azghadi S, Zhou W, Liu L, Jiang N, Li T, Gao T, Sweeney C, Shen R, Lin TY, Pan CX, Ozpiskin OM, Woloschak G, Grdina DJ, Vaughan AT, Wang JM, Xia S, Monjazeb AM, Murphy WJ, Sun LQ, Chen HW, Lam KS, Weichselbaum RR, Li JJ. Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells. Nat Commun 2020;11:4591. [PMID: 32929084 DOI: 10.1038/s41467-020-18245-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
116 Osei E, Francis R, Sheraz L. A review of radiation induced abscopal effect: combining radiotherapy and immunotherapy to treat the untreated distant metastatic tumours. J Radiother Pract 2022;21:117-24. [DOI: 10.1017/s1460396920000680] [Reference Citation Analysis]
117 Bozorgmehr F, Chung I, Christopoulos P, Krisam J, Schneider MA, Brückner L, Mueller DW, Thomas M, Rieken S. Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial. BMC Cancer 2020;20:806. [PMID: 32842974 DOI: 10.1186/s12885-020-07264-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
118 Powerski M, Drewes R, Omari J, Relja B, Surov A, Pech M. Intra-hepatic Abscopal Effect Following Radioembolization of Hepatic Metastases. Cardiovasc Intervent Radiol 2020;43:1641-9. [PMID: 32808201 DOI: 10.1007/s00270-020-02612-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
119 Kalanxhi E, Meltzer S, Ree AH. Immune-Modulating Effects of Conventional Therapies in Colorectal Cancer. Cancers 2020;12:2193. [DOI: 10.3390/cancers12082193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
120 Wang D, Zhang X, Gao Y, Cui X, Yang Y, Mao W, Li M, Zhang B, Yu J. Research Progress and Existing Problems for Abscopal Effect. Cancer Manag Res 2020;12:6695-706. [PMID: 32801902 DOI: 10.2147/CMAR.S245426] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
121 Sarihan S. IMMUNOTERAPİ VE RADYOTERAPİ KOMBİNASYONU. Uludağ Üniversitesi Tıp Fakültesi Dergisi 2020. [DOI: 10.32708/uutfd.710919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
122 Li J, Li H, Wang Y, Liu J, Wang X, Pang H, Chang D, Di Y, Ren G, Li P, Wang Y, Liu C, Chen X, Kang X, Xia T. Outcomes of Hypofractional Tomotherapy in Patients with Stage III Nonsmall Cell Lung Cancer Who Are Not Eligible for Surgery or Concurrent Chemoradiation. Biomed Res Int 2020;2020:9168424. [PMID: 32685544 DOI: 10.1155/2020/9168424] [Reference Citation Analysis]
123 Zucker A, Winter A, Lumley D, Karwowski P, Jung MK, Kao J. Prognostic role of baseline neutrophil-to-lymphocyte ratio in metastatic solid tumors. Mol Clin Oncol 2020;13:25. [PMID: 32774855 DOI: 10.3892/mco.2020.2095] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
124 Daguenet E, Louati S, Wozny AS, Vial N, Gras M, Guy JB, Vallard A, Rodriguez-Lafrasse C, Magné N. Radiation-induced bystander and abscopal effects: important lessons from preclinical models. Br J Cancer 2020;123:339-48. [PMID: 32581341 DOI: 10.1038/s41416-020-0942-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
125 Datta NR, Kok HP, Crezee H, Gaipl US, Bodis S. Integrating Loco-Regional Hyperthermia Into the Current Oncology Practice: SWOT and TOWS Analyses. Front Oncol 2020;10:819. [PMID: 32596144 DOI: 10.3389/fonc.2020.00819] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
126 Gómez V, Mustapha R, Ng K, Ng T. Radiation therapy and the innate immune response: Clinical implications for immunotherapy approaches. Br J Clin Pharmacol 2020;86:1726-35. [PMID: 32388875 DOI: 10.1111/bcp.14351] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
127 Chulpanova DS, Kitaeva KV, Green AR, Rizvanov AA, Solovyeva VV. Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy. Front Cell Dev Biol 2020;8:402. [PMID: 32582698 DOI: 10.3389/fcell.2020.00402] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 11.7] [Reference Citation Analysis]
128 Buss CG, Bhatia SN. Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics. Proc Natl Acad Sci U S A 2020;117:13428-36. [PMID: 32493746 DOI: 10.1073/pnas.2001569117] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
129 Li JJ. Mitigating Coronavirus-Induced Acute Respiratory Distress Syndrome by Radiotherapy. iScience 2020;23:101215. [PMID: 32512383 DOI: 10.1016/j.isci.2020.101215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
130 Rao G, Sonabend A, Heimberger AB. Are radiation and response biomarkers the missing elements for efficacious immunotherapy for glioma patients? Neuro Oncol 2020;22:590-1. [PMID: 31967642 DOI: 10.1093/neuonc/noaa018] [Reference Citation Analysis]
131 Wang J, Li Z, Wang Z, Yu Y, Li D, Li B, Ding J. Nanomaterials for Combinational Radio–Immuno Oncotherapy. Adv Funct Mater 2020;30:1910676. [DOI: 10.1002/adfm.201910676] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
132 Jagodinsky JC, Harari PM, Morris ZS. The Promise of Combining Radiation Therapy With Immunotherapy. Int J Radiat Oncol Biol Phys 2020;108:6-16. [PMID: 32335187 DOI: 10.1016/j.ijrobp.2020.04.023] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 16.7] [Reference Citation Analysis]
133 Mondini M, Levy A, Meziani L, Milliat F, Deutsch E. Radiotherapy-immunotherapy combinations - perspectives and challenges. Mol Oncol 2020;14:1529-37. [PMID: 32112478 DOI: 10.1002/1878-0261.12658] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 16.0] [Reference Citation Analysis]
134 McLaughlin M, Patin EC, Pedersen M, Wilkins A, Dillon MT, Melcher AA, Harrington KJ. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer 2020;20:203-17. [PMID: 32161398 DOI: 10.1038/s41568-020-0246-1] [Cited by in Crossref: 194] [Cited by in F6Publishing: 210] [Article Influence: 64.7] [Reference Citation Analysis]
135 Chi MS, Mehta MP, Yang KL, Lai HC, Lin YC, Ko HL, Wang YS, Liao KW, Chi KH. Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. Front Oncol 2020;10:254. [PMID: 32211319 DOI: 10.3389/fonc.2020.00254] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
136 Meng X, Feng R, Yang L, Xing L, Yu J. The Role of Radiation Oncology in Immuno-Oncology. Oncologist 2019;24:S42-52. [PMID: 30819830 DOI: 10.1634/theoncologist.2019-IO-S1-s04] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
137 Huang J, Li JJ. Cell repopulation, rewiring metabolism, and immune regulation in cancer radiotherapy. Radiation Medicine and Protection 2020;1:24-30. [DOI: 10.1016/j.radmp.2020.02.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
138 Demaria S, Formenti SC. The abscopal effect 67 years later: from a side story to center stage. Br J Radiol 2020;93:20200042. [PMID: 32101479 DOI: 10.1259/bjr.20200042] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 14.7] [Reference Citation Analysis]
139 Hong WX, Haebe S, Lee AS, Westphalen CB, Norton JA, Jiang W, Levy R. Intratumoral Immunotherapy for Early-stage Solid Tumors. Clin Cancer Res 2020;26:3091-9. [PMID: 32071116 DOI: 10.1158/1078-0432.CCR-19-3642] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 14.7] [Reference Citation Analysis]
140 Benna M, Guy JB, Bosacki C, Jmour O, Ben Mrad M, Ogorodniitchouk O, Soltani S, Lan M, Daguenet E, Mery B, Sotton S, Magné N, Vallard A. Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box? Br J Radiol 2020;93:20190147. [PMID: 31971824 DOI: 10.1259/bjr.20190147] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
141 Farias VA, Tovar I, Del Moral R, O'Valle F, Expósito J, Oliver FJ, Ruiz de Almodóvar JM. Enhancing the Bystander and Abscopal Effects to Improve Radiotherapy Outcomes. Front Oncol 2019;9:1381. [PMID: 31970082 DOI: 10.3389/fonc.2019.01381] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
142 Floyd W, Kuo H, Himes JE, Patel R, Kirsch DG. Genetically Engineered Mouse Models for Studying Radiation Biology and Radiosensitizers. Cancer Drug Discovery and Development 2020. [DOI: 10.1007/978-3-030-49701-9_8] [Reference Citation Analysis]
143 D'Andrea MA, Reddy GK. Extracranial systemic antitumor response through the abscopal effect induced by brain radiation in a patient with metastatic melanoma. Radiat Oncol J. 2019;37:302-308. [PMID: 31918469 DOI: 10.3857/roj.2019.00437] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
144 Ishiyama Y, Takagi T, Yoshida K, Iizuka J, Kakuta Y, Okumi M, Ishida H, Tanabe K. Possible abscopal effect in urothelial carcinoma of the upper urinary tract after treatment with immune checkpoint inhibitors. IJU Case Rep. 2020;3:25-27. [PMID: 32743462 DOI: 10.1002/iju5.12133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
145 Bonilla CE, Esguerra J, Mendoza Díaz S, Álvarez A, Morales R L. Abscopal Effect After Palliative Radiotherapy in a Patient with a Gastric Adenocarcinoma Disseminated to Retroperitoneal Space: Case Report from a Latin American Reference Center and Review of the Literature. Cureus 2019;11:e6235. [PMID: 31890434 DOI: 10.7759/cureus.6235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
146 Bozorgmehr F, Hommertgen A, Krisam J, Lasitschka F, Kuon J, Maenz M, Huber PE, König L, Kieser M, Debus J, Thomas M, Rieken S. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial. BMC Cancer 2019;19:1074. [PMID: 31703637 DOI: 10.1186/s12885-019-6205-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
147 Spaas M, Lievens Y. Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach? Front Med (Lausanne). 2019;6:244. [PMID: 31788476 DOI: 10.3389/fmed.2019.00244] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
148 Fabian A, Domschikowski J, Dunst J, Krug D. Lokal fortgeschrittenes nichtkleinzelliges Lungenkarzinom: Radioimmuntherapie als neuer Standard? Pneumologe 2019;16:366-372. [DOI: 10.1007/s10405-019-0265-3] [Reference Citation Analysis]
149 Golub D, Kwan K, Knisely JPS, Schulder M. Possible Abscopal Effect Observed in Frontal Meningioma After Localized IMRT on Posterior Meningioma Resection Cavity Without Adjuvant Immunotherapy. Front Oncol 2019;9:1109. [PMID: 31681619 DOI: 10.3389/fonc.2019.01109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
150 Giraud N, Giraud P. Radiothérapie et immunothérapie : nouveau standard, nouvelles options. Revue des Maladies Respiratoires Actualités 2019;11:S484-S490. [DOI: 10.1016/s2096-5192(19)30156-9] [Reference Citation Analysis]
151 Yu S, Cai L, Lin F, Wu X, Zhang C, Liu X, Li W. Durable Response After Combination Of Concurrent Chemoradiotherapy And Anti-PD-1 Therapy In HER2-Negative Advanced Gastric Adenocarcinoma: A Case Report. Onco Targets Ther. 2019;12:7691-7698. [PMID: 31571920 DOI: 10.2147/ott.s221436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
152 Hlavata Z, Solinas C, De Silva P, Porcu M, Saba L, Willard-Gallo K, Scartozzi M. The Abscopal Effect in the Era of Cancer Immunotherapy: a Spontaneous Synergism Boosting Anti-tumor Immunity? Target Oncol 2018;13:113-23. [PMID: 29470785 DOI: 10.1007/s11523-018-0556-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
153 Menon H, Chen D, Ramapriyan R, Verma V, Barsoumian HB, Cushman TR, Younes AI, Cortez MA, Erasmus JJ, de Groot P, Carter BW, Hong DS, Glitza IC, Ferrarotto R, Altan M, Diab A, Chun SG, Heymach JV, Tang C, Nguyen QN, Welsh JW. Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. J Immunother Cancer 2019;7:237. [PMID: 31484556 DOI: 10.1186/s40425-019-0718-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 11.5] [Reference Citation Analysis]
154 Liang L, Hu C, Wen Y, Geng X, Chen T, Gu G, Wang L, Xia Y, Liu Y, Fei J, Dong J, Zhao F, Ahongjiang Y, Hui K, Jiang X. Apatinib Combined with Local Irradiation Leads to Systemic Tumor Control via Reversal of Immunosuppressive Tumor Microenvironment in Lung Cancer. Cancer Res Treat 2020;52:406-18. [DOI: 10.4143/crt.2019.296] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
155 Nesbit EG, Leal TA, Kruser TJ. What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era? Transl Lung Cancer Res. 2019;8:S153-S162. [PMID: 31673520 DOI: 10.21037/tlcr.2019.05.01] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
156 Tabrizi S, Mcduff S, Ho AY. Combining Radiation Therapy with Immune Checkpoint Blockadein Breast Cancer. Curr Breast Cancer Rep 2019;11:203-16. [DOI: 10.1007/s12609-019-00327-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
157 Seitz C, Rückert M, Deloch L, Weiss EM, Utz S, Izydor M, Ebel N, Schlücker E, Fietkau R, Gaipl US, Frey B. Tumor Cell-Based Vaccine Generated With High Hydrostatic Pressure Synergizes With Radiotherapy by Generating a Favorable Anti-tumor Immune Microenvironment. Front Oncol 2019;9:805. [PMID: 31555582 DOI: 10.3389/fonc.2019.00805] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
158 Goto T. Radiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges. Vaccines (Basel) 2019;7:E100. [PMID: 31455032 DOI: 10.3390/vaccines7030100] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
159 Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, Schnurr M, Lauber K. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol 2019;14:141. [PMID: 31395068 DOI: 10.1186/s13014-019-1345-6] [Cited by in Crossref: 152] [Cited by in F6Publishing: 160] [Article Influence: 38.0] [Reference Citation Analysis]
160 Durante M, Formenti S. Harnessing radiation to improve immunotherapy: better with particles? Br J Radiol 2020;93:20190224. [PMID: 31317768 DOI: 10.1259/bjr.20190224] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
161 Zeng H, Zhang W, Gong Y, Xie C. Radiotherapy activates autophagy to increase CD8+ T cell infiltration by modulating major histocompatibility complex class-I expression in non-small cell lung cancer. J Int Med Res 2019;47:3818-30. [PMID: 31187666 DOI: 10.1177/0300060519855595] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
162 Dunst J, Bauerschlag D, Maass N, Krug D. Strahlentherapie bei Metastasen. Gynäkologe 2019;52:453-460. [DOI: 10.1007/s00129-019-4401-2] [Reference Citation Analysis]
163 Palata O, Hradilova Podzimkova N, Nedvedova E, Umprecht A, Sadilkova L, Palova Jelinkova L, Spisek R, Adkins I. Radiotherapy in Combination With Cytokine Treatment. Front Oncol 2019;9:367. [PMID: 31179236 DOI: 10.3389/fonc.2019.00367] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
164 Aliru ML, Schoenhals JE, Venkatesulu BP, Anderson CC, Barsoumian HB, Younes AI, K Mahadevan LS, Soeung M, Aziz KE, Welsh JW, Krishnan S. Radiation therapy and immunotherapy: what is the optimal timing or sequencing? Immunotherapy. 2018;10:299-316. [PMID: 29421979 DOI: 10.2217/imt-2017-0082] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 8.3] [Reference Citation Analysis]
165 Liu C, Hu Q, Xu B, Hu X, Su H, Li Q, Zhang X, Yue J, Yu J. Peripheral memory and naïve T cells in non-small cell lung cancer patients with lung metastases undergoing stereotactic body radiotherapy: predictors of early tumor response. Cancer Cell Int 2019;19:121. [PMID: 31080362 DOI: 10.1186/s12935-019-0839-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
166 Shi XX, Pang HW, Ren PR, Sun XY, Wu JB, Lin S. Template-assisted 192Ir-based stereotactic ablative brachytherapy as a neoadjuvant treatment for operable peripheral non-small cell lung cancer: a phase I clinical trial. J Contemp Brachytherapy 2019;11:162-8. [PMID: 31139225 DOI: 10.5114/jcb.2019.84613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
167 Kreidieh M, Zeidan YH, Shamseddine A. The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors. J Oncol. 2019;2019:4304817. [PMID: 31182960 DOI: 10.1155/2019/4304817] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
168 Ko EC, Galluzzi L. Radiation unlocks the therapeutic potential of immune checkpoint blockers in lung cancer patients. Oncoimmunology 2019;8:1606624. [PMID: 31413913 DOI: 10.1080/2162402X.2019.1606624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
169 Minniti G, Anzellini D, Reverberi C, Cappellini GCA, Marchetti L, Bianciardi F, Bozzao A, Osti M, Gentile PC, Esposito V. Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity. J Immunother Cancer 2019;7:102. [PMID: 30975225 DOI: 10.1186/s40425-019-0588-y] [Cited by in Crossref: 62] [Cited by in F6Publishing: 67] [Article Influence: 15.5] [Reference Citation Analysis]
170 Ding Y, Campbell WG, Miften M, Vinogradskiy Y, Goodman KA, Schefter T, Jones BL. Quantifying Allowable Motion to Achieve Safe Dose Escalation in Pancreatic SBRT. Pract Radiat Oncol 2019;9:e432-42. [PMID: 30951868 DOI: 10.1016/j.prro.2019.03.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
171 Belderbos RA, Aerts JGJV, Vroman H. Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment. Mol Ther Oncolytics 2019;13:67-81. [PMID: 31020037 DOI: 10.1016/j.omto.2019.03.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
172 Leary R, Gardner RB, Mockbee C, Roychowdhury DF. Boosting Abscopal Response to Radiotherapy with Sargramostim: A Review of Data and Ongoing Studies. Cureus 2019;11:e4276. [PMID: 31157137 DOI: 10.7759/cureus.4276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
173 Chen Q, Hu W, Xiong H, Ying S, Ruan Y, Wu B, Lu H. Changes in plasma EBV-DNA and immune status in patients with nasopharyngeal carcinoma after treatment with intensity-modulated radiotherapy. Diagn Pathol 2019;14:23. [PMID: 30871579 DOI: 10.1186/s13000-019-0798-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
174 Kirsch DG, Diehn M, Kesarwala AH, Maity A, Morgan MA, Schwarz JK, Bristow R, Demaria S, Eke I, Griffin RJ, Haas-Kogan D, Higgins GS, Kimmelman AC, Kimple RJ, Lombaert IM, Ma L, Marples B, Pajonk F, Park CC, Schaue D, Tran PT, Willers H, Wouters BG, Bernhard EJ. The Future of Radiobiology. J Natl Cancer Inst 2018;110:329-40. [PMID: 29126306 DOI: 10.1093/jnci/djx231] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 13.5] [Reference Citation Analysis]
175 Zappasodi R, Merghoub T, Wolchok JD. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. Cancer Cell. 2018;33:581-598. [PMID: 29634946 DOI: 10.1016/j.ccell.2018.03.005] [Cited by in Crossref: 282] [Cited by in F6Publishing: 250] [Article Influence: 70.5] [Reference Citation Analysis]
176 Kanegasaki S, Yamashita T, Tsuchiya T. Reduced Number of Lymphocytes by X-ray Irradiation: A Problem in a Combination Therapy Trial that Elicits the Abscopal Effect in Preclinical Studies Using Electron Beam Irradiation. Cureus 2019;11:e4142. [PMID: 31058025 DOI: 10.7759/cureus.4142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
177 Dagoglu N, Karaman S, Caglar HB, Oral EN. Abscopal Effect of Radiotherapy in the Immunotherapy Era: Systematic Review of Reported Cases. Cureus 2019;11:e4103. [PMID: 31057997 DOI: 10.7759/cureus.4103] [Cited by in Crossref: 24] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
178 Barsky AR, Cengel KA, Katz SI, Sterman DH, Simone CB 2nd. First-ever Abscopal Effect after Palliative Radiotherapy and Immuno-gene Therapy for Malignant Pleural Mesothelioma. Cureus 2019;11:e4102. [PMID: 31057996 DOI: 10.7759/cureus.4102] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
179 Ozpiskin OM, Zhang L, Li JJ. Immune targets in the tumor microenvironment treated by radiotherapy. Theranostics 2019;9:1215-31. [PMID: 30867826 DOI: 10.7150/thno.32648] [Cited by in Crossref: 46] [Cited by in F6Publishing: 60] [Article Influence: 11.5] [Reference Citation Analysis]
180 Tubin S, Popper HH, Brcic L. Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects. Radiat Oncol 2019;14:21. [PMID: 30696472 DOI: 10.1186/s13014-019-1227-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 10.3] [Reference Citation Analysis]
181 Seto T, Sam D, Pan M. Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer. Med Sci (Basel) 2019;7:E14. [PMID: 30678257 DOI: 10.3390/medsci7020014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
182 Fan TM, Selting KA. Exploring the Potential Utility of Pet Dogs With Cancer for Studying Radiation-Induced Immunogenic Cell Death Strategies. Front Oncol 2018;8:680. [PMID: 30697532 DOI: 10.3389/fonc.2018.00680] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
183 Dar TB, Henson RM, Shiao SL. Targeting Innate Immunity to Enhance the Efficacy of Radiation Therapy. Front Immunol 2018;9:3077. [PMID: 30692991 DOI: 10.3389/fimmu.2018.03077] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
184 Leaman Alcibar O, Candini D, López-Campos F, Albert Antequera M, Morillo Macías V, Conde AJ, Rodríguez Pérez A, Hervás Morón A, Contreras Martínez J, Ferrer Albiach C, Navarro Aguilar S, Rodríguez-Ruiz ME. Time for radioimmunotherapy: an overview to bring improvements in clinical practice. Clin Transl Oncol 2019;21:992-1004. [PMID: 30644044 DOI: 10.1007/s12094-018-02027-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
185 Goedegebuure RSA, de Klerk LK, Bass AJ, Derks S, Thijssen VLJL. Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer? Front Immunol 2018;9:3107. [PMID: 30692993 DOI: 10.3389/fimmu.2018.03107] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 13.5] [Reference Citation Analysis]
186 Frey B, Rückert M, Gaipl US. Immune Modulatory Effects of Radiotherapy. Radiation Oncology 2019. [DOI: 10.1007/978-3-319-52619-5_106-1] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
187 Wilke C, Cho LC, Sperduto PW. Patient Selection in SBRT and SRS. Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy 2019. [DOI: 10.1007/978-3-030-16924-4_29] [Reference Citation Analysis]
188 Jones JA, Karouia F, Pinsky L, Cristea O. Radiation and Radiation Disorders. Principles of Clinical Medicine for Space Flight 2019. [DOI: 10.1007/978-1-4939-9889-0_2] [Reference Citation Analysis]
189 Murshed H. Immunotherapy. Fundamentals of Radiation Oncology 2019. [DOI: 10.1016/b978-0-12-814128-1.00010-6] [Reference Citation Analysis]
190 Huang R, Cui Y, Guo Y. Programmed Cell Death Protein-1 Predicts the Recurrence of Breast Cancer in Patients Subjected to Radiotherapy After Breast-Preserving Surgery. Technol Cancer Res Treat 2018;17:1533033818793425. [PMID: 30122122 DOI: 10.1177/1533033818793425] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
191 Buchwald ZS, Wynne J, Nasti TH, Zhu S, Mourad WF, Yan W, Gupta S, Khleif SN, Khan MK. Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation. Front Oncol 2018;8:612. [PMID: 30619752 DOI: 10.3389/fonc.2018.00612] [Cited by in Crossref: 91] [Cited by in F6Publishing: 101] [Article Influence: 18.2] [Reference Citation Analysis]
192 Tsoutsou PG, Zaman K, Martin Lluesma S, Cagnon L, Kandalaft L, Vozenin MC. Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity. Front Oncol 2018;8:609. [PMID: 30619749 DOI: 10.3389/fonc.2018.00609] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
193 Locy H, de Mey S, de Mey W, De Ridder M, Thielemans K, Maenhout SK. Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend. Front Immunol 2018;9:2909. [PMID: 30619273 DOI: 10.3389/fimmu.2018.02909] [Cited by in Crossref: 98] [Cited by in F6Publishing: 115] [Article Influence: 19.6] [Reference Citation Analysis]
194 van Gulijk M, Dammeijer F, Aerts JGJV, Vroman H. Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy. Front Immunol 2018;9:2759. [PMID: 30568653 DOI: 10.3389/fimmu.2018.02759] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 7.6] [Reference Citation Analysis]
195 Gajiwala S, Torgeson A, Garrido-Laguna I, Kinsey C, Lloyd S. Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle. J Gastrointest Oncol 2018;9:1014-26. [PMID: 30603120 DOI: 10.21037/jgo.2018.05.16] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
196 Wang Y, Liu ZG, Yuan H, Deng W, Li J, Huang Y, Kim BYS, Story MD, Jiang W. The Reciprocity between Radiotherapy and Cancer Immunotherapy. Clin Cancer Res 2019;25:1709-17. [PMID: 30413527 DOI: 10.1158/1078-0432.CCR-18-2581] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 10.8] [Reference Citation Analysis]
197 Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C, Vanpouille-Box C, Friedman K, Ferrari de Andrade L, Wucherpfennig KW, Heguy A, Imai N, Gnjatic S, Emerson RO, Zhou XK, Zhang T, Chachoua A, Demaria S. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24:1845-1851. [PMID: 30397353 DOI: 10.1038/s41591-018-0232-2] [Cited by in Crossref: 412] [Cited by in F6Publishing: 433] [Article Influence: 82.4] [Reference Citation Analysis]
198 Poleszczuk J, Enderling H. The Optimal Radiation Dose to Induce Robust Systemic Anti-Tumor Immunity. Int J Mol Sci. 2018;19. [PMID: 30380596 DOI: 10.3390/ijms19113377] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
199 Samstein RM, Riaz N. The DNA damage response in immunotherapy and radiation. Adv Radiat Oncol 2018;3:527-33. [PMID: 30370352 DOI: 10.1016/j.adro.2018.08.017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
200 Ko EC, Benjamin KT, Formenti SC. Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation. Adv Radiat Oncol 2018;3:486-93. [PMID: 30370347 DOI: 10.1016/j.adro.2018.08.021] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 8.0] [Reference Citation Analysis]
201 Marciscano AE, Thorek DLJ. Role of noninvasive molecular imaging in determining response. Adv Radiat Oncol 2018;3:534-47. [PMID: 30370353 DOI: 10.1016/j.adro.2018.07.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
202 Medler T, Patel JM, Alice A, Baird JR, Hu HM, Gough MJ. Activating the Nucleic Acid-Sensing Machinery for Anticancer Immunity. Int Rev Cell Mol Biol 2019;344:173-214. [PMID: 30798988 DOI: 10.1016/bs.ircmb.2018.08.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
203 Desmet A, Van Schil P, Van Houtte P. Quelles stratégies thérapeutiques pour les CBNPC oligo-métastatiques ? Revue des Maladies Respiratoires Actualités 2018;10:326-331. [DOI: 10.1016/s1877-1203(18)30028-4] [Reference Citation Analysis]
204 Schaub SK, Stewart RD, Sandison GA, Arbuckle T, Liao JJ, Laramore GE, Zeng J, Rengan R, Tseng YD, Mayr NA, Bhatia S, Nghiem PT, Parvathaneni U. Does Neutron Radiation Therapy Potentiate an Immune Response to Merkel Cell Carcinoma? Int J Part Ther 2018;5:183-95. [PMID: 31773029 DOI: 10.14338/IJPT-18-00012.1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
205 McKelvey KJ, Hudson AL, Back M, Eade T, Diakos CI. Radiation, inflammation and the immune response in cancer. Mamm Genome 2018;29:843-65. [PMID: 30178305 DOI: 10.1007/s00335-018-9777-0] [Cited by in Crossref: 81] [Cited by in F6Publishing: 68] [Article Influence: 16.2] [Reference Citation Analysis]
206 Venkatesulu BP, Mahadevan LS, Aliru ML, Yang X, Bodd MH, Singh PK, Yusuf SW, Abe JI, Krishnan S. Radiation-Induced Endothelial Vascular Injury: A Review of Possible Mechanisms. JACC Basic Transl Sci 2018;3:563-72. [PMID: 30175280 DOI: 10.1016/j.jacbts.2018.01.014] [Cited by in Crossref: 99] [Cited by in F6Publishing: 78] [Article Influence: 19.8] [Reference Citation Analysis]
207 Liu Y, Dong Y, Kong L, Shi F, Zhu H, Yu J. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018;11:104. [PMID: 30115069 DOI: 10.1186/s13045-018-0647-8] [Cited by in Crossref: 172] [Cited by in F6Publishing: 188] [Article Influence: 34.4] [Reference Citation Analysis]
208 Patel RB, Baniel CC, Sriramaneni RN, Bradley K, Markovina S, Morris ZS. Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities. Brachytherapy 2018;17:995-1003. [PMID: 30078541 DOI: 10.1016/j.brachy.2018.07.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
209 Tumati V, Iyengar P. The current state of oligometastatic and oligoprogressive non-small cell lung cancer. J Thorac Dis 2018;10:S2537-44. [PMID: 30206497 DOI: 10.21037/jtd.2018.07.19] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
210 Rodríguez-Ruiz ME, Vanpouille-Box C, Melero I, Formenti SC, Demaria S. Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect. Trends Immunol 2018;39:644-55. [PMID: 30001871 DOI: 10.1016/j.it.2018.06.001] [Cited by in Crossref: 200] [Cited by in F6Publishing: 174] [Article Influence: 40.0] [Reference Citation Analysis]
211 Walker R, Poleszczuk J, Pilon-Thomas S, Kim S, Anderson AARA, Czerniecki BJ, Harrison LB, Moros EG, Enderling H. Immune interconnectivity of anatomically distant tumors as a potential mediator of systemic responses to local therapy. Sci Rep 2018;8:9474. [PMID: 29930290 DOI: 10.1038/s41598-018-27718-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
212 Day D, Monjazeb AM, Sharon E, Ivy SP, Rubin EH, Rosner GL, Butler MO. From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. Clin Cancer Res 2017;23:4980-91. [PMID: 28864726 DOI: 10.1158/1078-0432.CCR-16-3064] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
213 Mauti LA, Finazzi T, Früh M, Pless M, Zippelius A, Rothschild SI. Current and future developments of immunotherapy in lung cancer. memo 2018;11:122-131. [DOI: 10.1007/s12254-018-0411-3] [Reference Citation Analysis]
214 Wennerberg E, Vanpouille-Box C, Bornstein S, Yamazaki T, Demaria S, Galluzzi L. Immune recognition of irradiated cancer cells. Immunol Rev 2017;280:220-30. [PMID: 29027232 DOI: 10.1111/imr.12568] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 10.0] [Reference Citation Analysis]
215 Crittenden MR, Zebertavage L, Kramer G, Bambina S, Friedman D, Troesch V, Blair T, Baird JR, Alice A, Gough MJ. Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity. Sci Rep 2018;8:7012. [PMID: 29725089 DOI: 10.1038/s41598-018-25482-w] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 12.8] [Reference Citation Analysis]
216 Ko EC, Formenti SC. Radiotherapy and checkpoint inhibitors: a winning new combination? Ther Adv Med Oncol. 2018;10:1758835918768240. [PMID: 29662550 DOI: 10.1177/1758835918768240] [Cited by in Crossref: 63] [Cited by in F6Publishing: 70] [Article Influence: 12.6] [Reference Citation Analysis]
217 O'Konek JJ, Ambrosino E, Bloom AC, Pasquet L, Massilamany C, Xia Z, Terabe M, Berzofsky JA. Differential Regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin. Oncoimmunology 2018;7:e1439305. [PMID: 29900040 DOI: 10.1080/2162402X.2018.1439305] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
218 Du D, Song T, Dai H, Jing Z, Chen P, Wu S. Stereotactic body radiation therapy and thymosin alpha-1-induced anti-tumor effects in heavily pretreated, metastatic esophageal squamous cell carcinoma patients. Oncoimmunology 2018;7:e1450128. [PMID: 30221039 DOI: 10.1080/2162402X.2018.1450128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
219 Wang R, Zhou T, Liu W, Zuo L. Molecular mechanism of bystander effects and related abscopal/cohort effects in cancer therapy. Oncotarget 2018;9:18637-47. [PMID: 29719632 DOI: 10.18632/oncotarget.24746] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 9.2] [Reference Citation Analysis]
220 Jatoi I, Benson JR, Kunkler I. Hypothesis: can the abscopal effect explain the impact of adjuvant radiotherapy on breast cancer mortality? NPJ Breast Cancer 2018;4:8. [PMID: 29644338 DOI: 10.1038/s41523-018-0061-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
221 Mujoo K, Hunt CR, Pandita RK, Ferrari M, Krishnan S, Cooke JP, Hahn S, Pandita TK. Harnessing and Optimizing the Interplay between Immunotherapy and Radiotherapy to Improve Survival Outcomes. Mol Cancer Res 2018;16:1209-14. [PMID: 29592896 DOI: 10.1158/1541-7786.MCR-17-0743] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
222 Vilalta M, Brune J, Rafat M, Soto L, Graves EE. The role of granulocyte macrophage colony stimulating factor (GM-CSF) in radiation-induced tumor cell migration. Clin Exp Metastasis 2018;35:247-54. [PMID: 29536224 DOI: 10.1007/s10585-018-9877-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
223 Rückert M, Deloch L, Fietkau R, Frey B, Hecht M, Gaipl US. Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies. Strahlenther Onkol 2018;194:509-19. [PMID: 29500551 DOI: 10.1007/s00066-018-1287-1] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 13.8] [Reference Citation Analysis]
224 Deng G, Hu P, Zhang J, Liu Q, Liang N, Xie J, Qiao L, Luo H, Xu D, Liu F, Yu X, Liu Z, Lv Y, Zhang J. Elevated serum granulocyte-macrophage colony-stimulating factor levels during radiotherapy predict favorable outcomes in lung and esophageal cancer. Oncotarget 2016;7:85142-50. [PMID: 27835886 DOI: 10.18632/oncotarget.13202] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
225 Frantzi M, Klimou Z, Makridakis M, Zoidakis J, Latosinska A, Borràs DM, Janssen B, Giannopoulou I, Lygirou V, Lazaris AC, Anagnou NP, Mischak H, Roubelakis MG, Vlahou A. Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca2+ signaling in T24M-based bladder cancer models. Oncotarget 2016;7:70750-68. [PMID: 27683119 DOI: 10.18632/oncotarget.12218] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
226 Tsuchiya T, Shiraishi K, Nakagawa K, Kim JR, Kanegasaki S. Identification of the active portion of the CCL3 derivative reported to induce antitumor abscopal effect. Clin Transl Radiat Oncol 2018;10:7-12. [PMID: 29928700 DOI: 10.1016/j.ctro.2018.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
227 Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018;18:313-322. [PMID: 29449659 DOI: 10.1038/nrc.2018.6] [Cited by in Crossref: 542] [Cited by in F6Publishing: 567] [Article Influence: 108.4] [Reference Citation Analysis]
228 Schoenhals JE, Cushman TR, Cadena AP, Demaria S, Welsh JW. Immunomodulation with Radiation. Immunotherapy in Translational Cancer Research 2018. [DOI: 10.1002/9781118684535.ch12] [Reference Citation Analysis]
229 Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol 2018;36:1611-8. [PMID: 29437535 DOI: 10.1200/JCO.2017.76.2229] [Cited by in Crossref: 301] [Cited by in F6Publishing: 331] [Article Influence: 60.2] [Reference Citation Analysis]
230 Minion LE, Tewari KS. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition. Gynecol Oncol 2018;148:609-21. [PMID: 29666026 DOI: 10.1016/j.ygyno.2018.01.009] [Cited by in Crossref: 75] [Cited by in F6Publishing: 58] [Article Influence: 15.0] [Reference Citation Analysis]
231 Pakkala S, Owonikoko TK. Immune checkpoint inhibitors in small cell lung cancer. J Thorac Dis 2018;10:S460-7. [PMID: 29593891 DOI: 10.21037/jtd.2017.12.51] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
232 Rosenberg A, Mahalingam D. Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response. J Gastrointest Oncol. 2018;9:143-159. [PMID: 29564181 DOI: 10.21037/jgo.2018.01.13] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
233 Ngoi NYL, Heong V, Lee XW, Huang YQ, Thian YL, Choo BA, Lim D, Lim YW, Lim SE, Ilancheran A, Soong R, Tan DSP. Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer. Gynecol Oncol Rep 2018;24:1-5. [PMID: 29892689 DOI: 10.1016/j.gore.2018.01.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
234 Basler L, Andratschke N, Ehrbar S, Guckenberger M, Tanadini-Lang S. Modelling the immunosuppressive effect of liver SBRT by simulating the dose to circulating lymphocytes: an in-silico planning study. Radiat Oncol 2018;13:10. [PMID: 29357886 DOI: 10.1186/s13014-018-0952-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
235 Walle T, Martinez Monge R, Cerwenka A, Ajona D, Melero I, Lecanda F. Radiation effects on antitumor immune responses: current perspectives and challenges. Ther Adv Med Oncol 2018;10:1758834017742575. [PMID: 29383033 DOI: 10.1177/1758834017742575] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 23.0] [Reference Citation Analysis]
236 Demaria S, Coleman CN, Formenti SC. Radiotherapy: Changing the Game in Immunotherapy. Trends Cancer. 2016;2:286-294. [PMID: 27774519 DOI: 10.1016/j.trecan.2016.05.002] [Cited by in Crossref: 198] [Cited by in F6Publishing: 187] [Article Influence: 39.6] [Reference Citation Analysis]
237 Danish HH, Patel KR, Switchenko JM, Gillespie TW, Jhaveri J, Chowdhary M, Abugideiri M, Delman KA, Lawson DH, Khan MK. The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis. Melanoma Res 2016;26:595-603. [PMID: 27575390 DOI: 10.1097/CMR.0000000000000292] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
238 Gorin J, Ménager J, Guilloux Y, Chatal J, Gaschet J, Chérel M. Combining RAIT and Immune-Based Therapies to Overcome Resistance in Cancer? Resistance to Targeted Anti-Cancer Therapeutics 2018. [DOI: 10.1007/978-3-319-78238-6_9] [Reference Citation Analysis]
239 Ragulin YA. The combination of immunotherapy and radiation therapy for non-small cell lung cancer. Onkol Z im P A Gercena 2018;7:90. [DOI: 10.17116/onkolog2018705190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
240 Demaria S, Bornstein S, Formenti SC. Synergy Between Radiotherapy and Immunotherapy. Oncoimmunology 2018. [DOI: 10.1007/978-3-319-62431-0_30] [Reference Citation Analysis]
241 Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH. Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer. Oncotarget 2016;7:34907-17. [PMID: 27145458 DOI: 10.18632/oncotarget.8995] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
242 Zhu N, Qin R, Zhang Q, Fu S, Liu S, Chen Y, Fan J, Han Y. Efficacy of granulocyte-macrophage colony-stimulating factor combined with metronomic paclitaxel in the treatment of Lewis lung carcinoma transplanted in mice. Oncotarget 2018;9:4951-60. [PMID: 29435154 DOI: 10.18632/oncotarget.23530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
243 Vatner RE, Janssen EM. STING, DCs and the link between innate and adaptive tumor immunity. Mol Immunol 2019;110:13-23. [PMID: 29273394 DOI: 10.1016/j.molimm.2017.12.001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 9.2] [Reference Citation Analysis]
244 Nordmann N, Hubbard M, Nordmann T, Sperduto PW, Clark HB, Hunt MA. Effect of Gamma Knife Radiosurgery and Programmed Cell Death 1 Receptor Antagonists on Metastatic Melanoma. Cureus 2017;9:e1943. [PMID: 29468099 DOI: 10.7759/cureus.1943] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
245 Garibaldi C, Jereczek-Fossa BA, Marvaso G, Dicuonzo S, Rojas DP, Cattani F, Starzyńska A, Ciardo D, Surgo A, Leonardi MC, Ricotti R. Recent advances in radiation oncology. Ecancermedicalscience 2017;11:785. [PMID: 29225692 DOI: 10.3332/ecancer.2017.785] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 9.5] [Reference Citation Analysis]
246 Martin-Liberal J, Hierro C, Ochoa de Olza M, Rodon J. Immuno-Oncology: The Third Paradigm in Early Drug Development. Target Oncol 2017;12:125-38. [PMID: 27995439 DOI: 10.1007/s11523-016-0471-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
247 Jensen GL, Blanchard P, Gunn GB, Garden AS, David Fuller C, Sturgis EM, Gillison ML, Phan J, Morrison WH, Rosenthal DI, Frank SJ. Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer. Clin Transl Radiat Oncol 2017;7:28-35. [PMID: 29594226 DOI: 10.1016/j.ctro.2017.09.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
248 Veisi Z, Ravanshadi S, Khadem H, Veisi Z, Ravanshadi S, Khadem H. Investigation of the Effect of Adding Stem Cells-as an Therapeutic Suggestion-on the Immune System's Response to the Cancerous Cells: A Mathematical Approach. 2017 24th National and 2nd International Iranian Conference on Biomedical Engineering (ICBME) 2017. [DOI: 10.1109/icbme.2017.8430249] [Reference Citation Analysis]
249 Schernberg A, Blanchard P, Chargari C, Deutsch E. Neutrophils, a candidate biomarker and target for radiation therapy? Acta Oncol 2017;56:1522-30. [PMID: 28835188 DOI: 10.1080/0284186X.2017.1348623] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
250 Chen YJ, Tsai TH, Wang LY, Hsieh CH. Local Radiotherapy Affects Drug Pharmacokinetics-Exploration of a Neglected but Significant Uncertainty of Cancer Therapy. Technol Cancer Res Treat 2017;16:705-16. [PMID: 29332468 DOI: 10.1177/1533034617737011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
251 Olson BM, Gamat M, Seliski J, Sawicki T, Jeffery J, Ellis L, Drake CG, Weichert J, McNeel DG. Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells. Cancer Immunol Res 2017;5:1074-85. [PMID: 29051161 DOI: 10.1158/2326-6066.CIR-16-0390] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
252 Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, Sanduleanu S, Larue RTHM, Even AJG, Jochems A, van Wijk Y, Woodruff H, van Soest J, Lustberg T, Roelofs E, van Elmpt W, Dekker A, Mottaghy FM, Wildberger JE, Walsh S. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749-762. [PMID: 28975929 DOI: 10.1038/nrclinonc.2017.141] [Cited by in Crossref: 1825] [Cited by in F6Publishing: 1968] [Article Influence: 304.2] [Reference Citation Analysis]
253 Tubin S, Raunik W. Hunting for abscopal and bystander effects: clinical exploitation of non-targeted effects induced by partial high-single-dose irradiation of the hypoxic tumour segment in oligometastatic patients. Acta Oncol 2017;56:1333-9. [PMID: 28686524 DOI: 10.1080/0284186X.2017.1346385] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
254 Rückert M, Deloch L, Fietkau R, Frey B, Gaipl US. Interaktionen von Strahlen- und Immuntherapie. Onkologe 2017;23:823-830. [DOI: 10.1007/s00761-017-0267-x] [Reference Citation Analysis]
255 Shi F, Wang X, Teng F, Kong L, Yu J. Abscopal effect of metastatic pancreatic cancer after local radiotherapy and granulocyte-macrophage colony-stimulating factor therapy. Cancer Biol Ther 2017;18:137-41. [PMID: 28267380 DOI: 10.1080/15384047.2016.1276133] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
256 Moynihan KD, Irvine DJ. Roles for Innate Immunity in Combination Immunotherapies. Cancer Res 2017;77:5215-21. [PMID: 28928130 DOI: 10.1158/0008-5472.CAN-17-1340] [Cited by in Crossref: 60] [Cited by in F6Publishing: 64] [Article Influence: 10.0] [Reference Citation Analysis]
257 Bergsma DP, Salama JK, Singh DP, Chmura SJ, Milano MT. Radiotherapy for Oligometastatic Lung Cancer. Front Oncol. 2017;7:210. [PMID: 28975081 DOI: 10.3389/fonc.2017.00210] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
258 Pianko MJ, Moskowitz AJ, Lesokhin AM. Immunotherapy of Lymphoma and Myeloma: Facts and Hopes. Clin Cancer Res 2018;24:1002-10. [PMID: 28899972 DOI: 10.1158/1078-0432.CCR-17-0539] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
259 Cabo M, Offringa R, Zitvogel L, Kroemer G, Muntasell A, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. Oncoimmunology 2017;6:e1371896. [PMID: 29209572 DOI: 10.1080/2162402X.2017.1371896] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
260 Shen J, Wang LF, Zou ZY, Kong WW, Yan J, Meng FY, Chen FJ, Du J, Shao J, Xu QP, Ren HZ, Li RT, Wei J, Qian XP, Liu BR. Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(29): 5395-5404 [PMID: 28839440 DOI: 10.3748/wjg.v23.i29.5395] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
261 Zhang T, Yu H, Ni C, Zhang T, Liu L, Lv Q, Zhang Z, Wang Z, Wu D, Wu P, Chen G, Wang L, Wei Q, Huang J, Wang X. Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage I non-small-cell lung cancer. Sci Rep 2017;7:4866. [PMID: 28687760 DOI: 10.1038/s41598-017-04978-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 3.8] [Reference Citation Analysis]
262 Poleszczuk J, Luddy K, Chen L, Lee JK, Harrison LB, Czerniecki BJ, Soliman H, Enderling H. Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival. Breast Cancer Res 2017;19:75. [PMID: 28666457 DOI: 10.1186/s13058-017-0870-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 7.7] [Reference Citation Analysis]
263 Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discov 2017;7:675-93. [PMID: 28630051 DOI: 10.1158/2159-8290.CD-17-0226] [Cited by in Crossref: 363] [Cited by in F6Publishing: 380] [Article Influence: 60.5] [Reference Citation Analysis]
264 Guo H, Tsung K. Tumor reductive therapies and antitumor immunity. Oncotarget 2017;8:55736-49. [PMID: 28903456 DOI: 10.18632/oncotarget.18469] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
265 Ponzio G, Rezzonico R, Bourget I, Allan R, Nottet N, Popa A, Magnone V, Rios G, Mari B, Barbry P. A new long noncoding RNA (lncRNA) is induced in cutaneous squamous cell carcinoma and down-regulates several anticancer and cell differentiation genes in mouse. J Biol Chem 2017;292:12483-95. [PMID: 28596382 DOI: 10.1074/jbc.M117.776260] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
266 Zhang J, Liu Q, Qiao L, Hu P, Deng G, Liang N, Xie J, Luo H, Zhang J. Novel role of granulocyte-macrophage colony-stimulating factor: antitumor effects through inhibition of epithelial-to-mesenchymal transition in esophageal cancer. Onco Targets Ther 2017;10:2227-37. [PMID: 28461757 DOI: 10.2147/OTT.S133504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
267 Ngwa W, Ouyang Z. Following the Preclinical Data: Leveraging the Abscopal Effect More Efficaciously. Front Oncol 2017;7:66. [PMID: 28447024 DOI: 10.3389/fonc.2017.00066] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
268 Wennerberg E, Lhuillier C, Vanpouille-Box C, Pilones KA, García-Martínez E, Rudqvist NP, Formenti SC, Demaria S. Barriers to Radiation-Induced In Situ Tumor Vaccination. Front Immunol 2017;8:229. [PMID: 28348554 DOI: 10.3389/fimmu.2017.00229] [Cited by in Crossref: 117] [Cited by in F6Publishing: 124] [Article Influence: 19.5] [Reference Citation Analysis]
269 Hu ZI, McArthur HL, Ho AY. The Abscopal Effect of Radiation Therapy: What Is It and How Can We Use It in Breast Cancer? Curr Breast Cancer Rep 2017;9:45-51. [PMID: 28344743 DOI: 10.1007/s12609-017-0234-y] [Cited by in Crossref: 95] [Cited by in F6Publishing: 105] [Article Influence: 15.8] [Reference Citation Analysis]
270 Marconi R, Strolin S, Bossi G, Strigari L. A meta-analysis of the abscopal effect in preclinical models: Is the biologically effective dose a relevant physical trigger? PLoS One 2017;12:e0171559. [PMID: 28222111 DOI: 10.1371/journal.pone.0171559] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 11.0] [Reference Citation Analysis]
271 Sato H, Suzuki Y, Yoshimoto Y, Noda SE, Murata K, Takakusagi Y, Okazaki A, Sekihara T, Nakano T. An abscopal effect in a case of concomitant treatment of locally and peritoneally recurrent gastric cancer using adoptive T-cell immunotherapy and radiotherapy. Clin Case Rep 2017;5:380-4. [PMID: 28396751 DOI: 10.1002/ccr3.758] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
272 Hillman GG, Reich LA, Rothstein SE, Abernathy LM, Fountain MD, Hankerd K, Yunker CK, Rakowski JT, Quemeneur E, Slos P. Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen. J Immunother Cancer 2017;5:4. [PMID: 28116088 DOI: 10.1186/s40425-016-0204-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
273 Lambin P, Zindler J, Vanneste BG, De Voorde LV, Eekers D, Compter I, Panth KM, Peerlings J, Larue RT, Deist TM, Jochems A, Lustberg T, van Soest J, de Jong EE, Even AJ, Reymen B, Rekers N, van Gisbergen M, Roelofs E, Carvalho S, Leijenaar RT, Zegers CM, Jacobs M, van Timmeren J, Brouwers P, Lal JA, Dubois L, Yaromina A, Van Limbergen EJ, Berbee M, van Elmpt W, Oberije C, Ramaekers B, Dekker A, Boersma LJ, Hoebers F, Smits KM, Berlanga AJ, Walsh S. Decision support systems for personalized and participative radiation oncology. Adv Drug Deliv Rev 2017;109:131-53. [PMID: 26774327 DOI: 10.1016/j.addr.2016.01.006] [Cited by in Crossref: 73] [Cited by in F6Publishing: 86] [Article Influence: 12.2] [Reference Citation Analysis]
274 Feng KC, Guo YL, Liu Y, Dai HR, Wang Y, Lv HY, Huang JH, Yang QM, Han WD. Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol. 2017;10:4. [PMID: 28057014 DOI: 10.1186/s13045-016-0378-7] [Cited by in Crossref: 109] [Cited by in F6Publishing: 120] [Article Influence: 18.2] [Reference Citation Analysis]
275 Li JJ. Cancer Stem Cells and Tumor Microenvironment in Radiotherapy. Cancer Treatment and Research 2017. [DOI: 10.1007/978-3-319-53235-6_9] [Reference Citation Analysis]
276 Balogun O, Formenti SC. Combining Radiotherapy and Immunotherapy. Cancer Treatment and Research 2017. [DOI: 10.1007/978-3-319-53235-6_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
277 Mellon EA, Murimwa G, Hoffe SE. Radiation Therapy for Liver Tumors: Future Directions. Radiation Therapy for Liver Tumors 2017. [DOI: 10.1007/978-3-319-54531-8_20] [Reference Citation Analysis]
278 Whiteside TL, Demaria S, Rodriguez-Ruiz ME, Zarour HM, Melero I. Emerging Opportunities and Challenges in Cancer Immunotherapy. Clin Cancer Res. 2016;22:1845-1855. [PMID: 27084738 DOI: 10.1158/1078-0432.ccr-16-0049] [Cited by in Crossref: 182] [Cited by in F6Publishing: 193] [Article Influence: 26.0] [Reference Citation Analysis]
279 Desar IM, Braam PM, Kaal SE, Gerritsen WR, Oyen WJ, van der Graaf WT. Abscopal effect of radiotherapy in a patient with metastatic diffuse-type giant cell tumor. Acta Oncol 2016;55:1510-2. [PMID: 27820978 DOI: 10.1080/0284186X.2016.1243805] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
280 Ascierto PA, Ascierto ML, Formenti S, Gnjatic S, Hammers H, Hirsh V, Kiessling R, Melero I, Nanda R, Pawelec G, Pignata S, Romero P, Speiser DE, Fox BA, Marincola FM. Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015. j immunotherapy cancer 2016;4. [DOI: 10.1186/s40425-016-0168-3] [Reference Citation Analysis]
281 Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer 2016;4:59. [PMID: 27777769 DOI: 10.1186/s40425-016-0165-6] [Cited by in Crossref: 312] [Cited by in F6Publishing: 330] [Article Influence: 44.6] [Reference Citation Analysis]
282 Orton A, Wright J, Buchmann L, Randall L, Hitchcock YJ. A Case of Complete Abscopal Response in High-Grade Pleiomorphic Sarcoma Treated with Radiotherapy Alone. Cureus 2016;8:e821. [PMID: 27843739 DOI: 10.7759/cureus.821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
283 Spiotto M, Fu YX, Weichselbaum RR. The intersection of radiotherapy and immunotherapy: Mechanisms and clinical implications. Sci Immunol. 2016;1:28018989. [PMID: 28018989 DOI: 10.1126/sciimmunol.aag1266] [Cited by in Crossref: 102] [Cited by in F6Publishing: 107] [Article Influence: 14.6] [Reference Citation Analysis]
284 Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res 2016;4:948-58. [PMID: 27688020 DOI: 10.1158/2326-6066.CIR-16-0042] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
285 Alexander GS, Palmer JD, Tuluc M, Lin J, Dicker AP, Bar-Ad V, Harshyne LA, Louie J, Shaw CM, Hooper DC, Lu B. Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy. J Hematol Oncol 2016;9:96. [PMID: 27663515 DOI: 10.1186/s13045-016-0328-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
286 Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017;23:1388-1396. [PMID: 27649551 DOI: 10.1158/1078-0432.ccr-16-1432] [Cited by in Crossref: 188] [Cited by in F6Publishing: 214] [Article Influence: 26.9] [Reference Citation Analysis]
287 Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer. 2016;4:51. [PMID: 27660705 DOI: 10.1186/s40425-016-0156-7] [Cited by in Crossref: 261] [Cited by in F6Publishing: 278] [Article Influence: 37.3] [Reference Citation Analysis]
288 Formenti SC, Demaria S, Barcellos-Hoff MH, McBride WH. Subverting misconceptions about radiation therapy. Nat Immunol 2016;17:345. [PMID: 27002831 DOI: 10.1038/ni.3363] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
289 Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology 2016;5:e1214790. [PMID: 27757313 DOI: 10.1080/2162402X.2016.1214790] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 7.7] [Reference Citation Analysis]
290 Habets TH, Oth T, Houben AW, Huijskens MJ, Senden-Gijsbers BL, Schnijderberg MC, Brans B, Dubois LJ, Lambin P, De Saint-Hubert M, Germeraad WT, Tilanus MG, Mottaghy FM, Bos GM, Vanderlocht J. Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response. PLoS One 2016;11:e0159515. [PMID: 27427766 DOI: 10.1371/journal.pone.0159515] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
291 Zschaeck S, Baumann M. [Not Available]. Strahlenther Onkol 2016;192:675-6. [PMID: 27402387 DOI: 10.1007/s00066-016-1017-5] [Reference Citation Analysis]
292 Formenti SC. The Pace of Progress in Radiation and Immunotherapy. International Journal of Radiation Oncology*Biology*Physics 2016;95:1257-8. [DOI: 10.1016/j.ijrobp.2016.02.063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
293 Deloch L, Derer A, Hartmann J, Frey B, Fietkau R, Gaipl US. Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation. Front Oncol 2016;6:141. [PMID: 27379203 DOI: 10.3389/fonc.2016.00141] [Cited by in Crossref: 90] [Cited by in F6Publishing: 93] [Article Influence: 12.9] [Reference Citation Analysis]
294 Kim SK, Wu CC, Horowitz DP. Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist. J Gastrointest Oncol 2016;7:479-86. [PMID: 27284482 DOI: 10.21037/jgo.2015.10.01] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
295 Finkel P, Frey B, Mayer F, Bösl K, Werthmöller N, Mackensen A, Gaipl US, Ullrich E. The dual role of NK cells in antitumor reactions triggered by ionizing radiation in combination with hyperthermia. Oncoimmunology 2016;5:e1101206. [PMID: 27471606 DOI: 10.1080/2162402X.2015.1101206] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
296 Sharma RA, Plummer R, Stock JK, Greenhalgh TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, Brown SR, Buckland S, Bulbeck H, Chalmers AJ, Clack G, Cranston AN, Damstrup L, Ferraldeschi R, Forster MD, Golec J, Hagan RM, Hall E, Hanauske AR, Harrington KJ, Haswell T, Hawkins MA, Illidge T, Jones H, Kennedy AS, McDonald F, Melcher T, O'Connor JP, Pollard JR, Saunders MP, Sebag-Montefiore D, Smitt M, Staffurth J, Stratford IJ, Wedge SR; NCRI CTRad Academia-Pharma Joint Working Group. Clinical development of new drug-radiotherapy combinations. Nat Rev Clin Oncol 2016;13:627-42. [PMID: 27245279 DOI: 10.1038/nrclinonc.2016.79] [Cited by in Crossref: 172] [Cited by in F6Publishing: 181] [Article Influence: 24.6] [Reference Citation Analysis]
297 Tiffen JC, Gallagher SJ, Tseng HY, Filipp FV, Fazekas de St. Groth B, Hersey P. EZH2 as a mediator of treatment resistance in melanoma. Pigment Cell Melanoma Res 2016;29:500-7. [PMID: 27063195 DOI: 10.1111/pcmr.12481] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
298 Demaria S, Formenti SC. Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking? J Immunother Cancer 2016;4:29. [PMID: 27190630 DOI: 10.1186/s40425-016-0133-1] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
299 Martin Lluesma S, Wolfer A, Harari A, Kandalaft LE. Cancer Vaccines in Ovarian Cancer: How Can We Improve? Biomedicines 2016;4:E10. [PMID: 28536377 DOI: 10.3390/biomedicines4020010] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
300 Ng J, Dai T. Radiation therapy and the abscopal effect: a concept comes of age. Ann Transl Med 2016;4:118. [PMID: 27127771 DOI: 10.21037/atm.2016.01.32] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 6.3] [Reference Citation Analysis]
301 Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer 2016;2:165-202. [PMID: 27376138 DOI: 10.3233/BLC-160053] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
302 Vilalta M, Rafat M, Graves EE. Effects of radiation on metastasis and tumor cell migration. Cell Mol Life Sci 2016;73:2999-3007. [PMID: 27022944 DOI: 10.1007/s00018-016-2210-5] [Cited by in Crossref: 69] [Cited by in F6Publishing: 73] [Article Influence: 9.9] [Reference Citation Analysis]
303 Price JG, Idoyaga J, Merad M. Reply to: "Subverting misconceptions about radiation therapy". Nat Immunol 2016;17:345-6. [PMID: 27002832 DOI: 10.1038/ni.3376] [Reference Citation Analysis]
304 Formenti SC, Golden EB, Demaria S. Local radiotherapy and GM-CSF in metastatic cancer: lessons from a proof of principle trial. OncoImmunology 2016. [DOI: 10.1080/2162402x.2015.1102830] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
305 Tamihardja J, Flentje M. Radiatio und Immuntherapien: Auf Suche nach Synergien. Deutsches Ärzteblatt Online 2016. [DOI: 10.3238/personko/2016.02.12.09] [Reference Citation Analysis]
306 Wong KK, Li WA, Mooney DJ, Dranoff G. Advances in Therapeutic Cancer Vaccines. Advances in Immunology 2016. [DOI: 10.1016/bs.ai.2015.12.001] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 10.3] [Reference Citation Analysis]
307 Schoenhals JE, Brooks ED, Cortez MA, Seyedin SN, Niknam S, Wang X, Cadena AP, Li XS, Gomez DR, Liao Z, Welsh JW. Translational Research and Immunotherapy in Lung Cancer. Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies 2016. [DOI: 10.1007/978-3-319-28761-4_12] [Reference Citation Analysis]
308 Brunet LR, Hagemann T, Andrew G, Mudan S, Marabelle A. Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? Oncoimmunology. 2016;5:e1112942. [PMID: 27141395 DOI: 10.1080/2162402x.2015.1112942] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
309 Vacchelli E, Aranda F, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology 2016;5:e1115942. [PMID: 27057468 DOI: 10.1080/2162402X.2015.1115942] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
310 Kumari A, Simon SS, Moody TD, Garnett-Benson C. Immunomodulatory effects of radiation: what is next for cancer therapy? Future Oncol 2016;12:239-56. [PMID: 26621553 DOI: 10.2217/fon.15.300] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
311 Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. J Transl Med 2015;13:374. [PMID: 26619946 DOI: 10.1186/s12967-015-0736-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
312 Derer A, Frey B, Fietkau R, Gaipl US. Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. Cancer Immunol Immunother 2016;65:779-86. [DOI: 10.1007/s00262-015-1771-8] [Cited by in Crossref: 98] [Cited by in F6Publishing: 110] [Article Influence: 12.3] [Reference Citation Analysis]
313 Derer A, Deloch L, Rubner Y, Fietkau R, Frey B, Gaipl US. Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. Front Immunol 2015;6:505. [PMID: 26500646 DOI: 10.3389/fimmu.2015.00505] [Cited by in Crossref: 69] [Cited by in F6Publishing: 75] [Article Influence: 8.6] [Reference Citation Analysis]
314 Lock M, Muinuddin A, Kocha WI, Dinniwell R, Rodrigues G, D'souza D. Abscopal Effects: Case Report and Emerging Opportunities. Cureus 2015;7:e344. [PMID: 26623199 DOI: 10.7759/cureus.344] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
315 Hutchinson L. Radiotherapy: abscopal responses: pro-immunogenic effects of radiotherapy. Nat Rev Clin Oncol 2015;12:504. [PMID: 26169925 DOI: 10.1038/nrclinonc.2015.127] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
316 Simone CB 2nd, Berman AT, Jabbour SK. Harnessing the potential synergy of combining radiation therapy and immunotherapy for thoracic malignancies. Transl Lung Cancer Res 2017;6:109-12. [PMID: 28529893 DOI: 10.21037/tlcr.2017.04.05] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
317 Campbell AM, Decker RH. Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res 2017;6:220-9. [PMID: 28529904 DOI: 10.21037/tlcr.2017.03.02] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
318 Kalbasi A, Rengan R. Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma. Transl Lung Cancer Res 2017;6:169-77. [PMID: 28529899 DOI: 10.21037/tlcr.2017.03.03] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
319 Alley EW, Katz SI, Cengel KA, Simone CB 2nd. Immunotherapy and radiation therapy for malignant pleural mesothelioma. Transl Lung Cancer Res 2017;6:212-9. [PMID: 28529903 DOI: 10.21037/tlcr.2017.04.01] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]